Replies to post #232047 on Amarin Corp Plc (AMRN)

[HDGabor]

M-

(More likely) no one did that ever … (usually) the RoW [all together*] is 50(-70%) of the US.

* "plus" V won't be sold in Japan, in one of the biggest market

Best,
G

[KCSVEN]

They will only earn royalties from those locations but generally yes. Peak Sales include all but majority USA.

[couldbebetter]

Magwitch, Canada is about 10% of the US population so Vascepa sales there
are not likely to be any higher than 10% of US sales, also, AMRN will
only get a certain % royalty. That will take time as HLS has no sales
force...but they plan on hiring some people to sell Vascepa.

My guess on Europe is the that the total market is larger than the US
market for Vascepa, but normally drugs there are sold at a 1/3 discount
to the US price... so I believe in a takeout of AMRN, the value given
for the US will be about equal to that given to Europe.

Most analysts only use US sales in their peak revenues projection.
Keep in mind that Vascepa is not approved for sale in Europe. Some
analysts will change their numbers once official approvals have been
had.

[Optionsrbest4u]

Re Peak Sales in the European Region (EU-28)

No idea, but there are roughly 510M people in EU-28 with roughly 98M age 65 and over. There are an estimated 50 to 60M diabetics (not sure what percentage of those are actually diagnosed diabetics).

If their population is similar to the US (re. age/diabetes), then roughly 25% of those 98M have diabetes (likely with at least one other risk factor)... so ~ 25M diabetic target population (diabetics 65 and over).

Anybody's guess as regards how much the EU will end up paying annually for Vascepa (though some have guesstimated closer to $1200 than $1600).


https://ec.europa.eu/eurostat/statistics-explained/index.php/People_in_the_EU_-_statistics_on_an_ageing_society

http://www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics